After more than 10 years of development, Qingdao Eastsea Pharmaceutical Co.Ltd. has become a specialized microecological enterprise of Drugs research and production, as well as the first microecological enterprise whose drugs have independent intellectual property right. With more than 10 years development the Institute create nine new drugs with independent intellectual property right, including three Grade1 biological medicine, two Grade2 biological medicine, one Grade3 Chinese traditional medicine and three Grade4 biological medicine; formed a powerful scientific research group which has 11 department, including strain abstraction and appreciation,physical chemistry analysis, gene molecular biology detection, zymotechnique research, new form of medication, pharmacology and pharmacodynamic action research, toxicant research,pharmacology metabolism research, clinical observation research,etc. They also have the full set of institution and equipment used for the creation of microecological drug industrialization.

Till now Eastsea have applied 15 national patents and 4 USA patents ( Applic No.: US11/191,712,US11/707,607,US11/763,072,US11/763,094). The 20 years patent protection gave Eastsea the chance of sustainable development and market monopoly. Eastsea science and research group had published more than 50 scientific research articles on the core periodical at home and abroad, assumed the responsibility of one new drug tackle key program of Ministry of Science and Technology, one national cooperation project( Program No.: 96-901-05-145 ) four “863”programs (Program No.: 2001AA214221,2003AA2Z3362,2004AA2Z3C50,2004AA001560, two small and medium enterprise creation found projects (Program No.: 01C26211100765,02C26211100486), one National Development and Reform Commission microecological drugs High-tech industrialization demonstration project and four technological development projects to the city of Qingdao. Eastsea published the first Clostridium Butyricum monograph at home and abroad on January 2008, this book settled rationale to the intestinal tract disease treatment and the generalization of Clostridium Butyricum.